Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The market dynamics of Scleritis revolve around addressing the complexities of this inflammatory eye condition, emphasizing the need for effective treatments and specialized care. Understanding the multifaceted factors influencing this dynamic healthcare sector is crucial for providing comprehensive solutions for individuals affected by scleritis.
The hallmark of the Scleritis market is the lower prevalence in contrast to the other eye troubles of the world. On the other hand, the extensity of vision loss and general eye health conditions for which are Brownian motion is highly relevant therefore, this makes it the main focus of specialized treatments and ongoing research efforts.
The market is heavily determined by patients association towards autoimmune and systemic diseases and as an effect of scleritis. The fact of identifying the background diseases, like rheumatoid arthritis and lupus, creates room for establishment of targeted therapies and gives shape to the landscape of the scleritis treatment.
This market can, consequently, be greatly affected with technological improvements within opthalmology. Techniques of advanced image like optical coherence tomography (OCT) and ultrasonography are among the fastest and best ways of early and accurate diagnostic procedures, guiding the treatment and impacting the outcome of patients.
As for the distinguishing point in management of scleritis, multidisciplinary approach is borne in mind. An ophthalmologist, a rheumatologist, and another specialist team up for more holistic provision of a care that targets both the ocular and the systemic problem(s) associated with the disease which greatly impact the market dynamics.
Rarity of the scleritis has paved way for the comfortable altonement of certain medicines by the designation of orphan status and the development of orphan drugs. The regulatory stimuli initiate a therapeutic process to end scleritis and contribute to reshaping market forces as well as motivating the drug companies to discover and introduce specific anti-scleritis drugs.
The role of patients' advocacy groups (PAGs) and support networks in the shaping of the market dynamics cannot be emphasized enough. Deciding a way forward from scleritis can be hard; however the organizations that raise awareness do not only give out information but in turn they fight for the good of patients. As a result, patient support is enhanced.
The adoption of telemedicine in ophthalmology is influencing market dynamics. Remote consultations, teleophthalmology services, and digital platforms for monitoring and follow-up care contribute to improved accessibility, especially for individuals managing scleritis.
The cost of specialized care, diagnostic procedures, and medications for scleritis is a significant consideration. Affordability and reimbursement policies impact patient access to these specialized treatments, influencing market dynamics and healthcare outcomes.
Scleritis Market Highlights:
Scleritis Market Overview
Scleritis Market Size was valued at USD 2.9 Billion in 2023. The Global Scleritis industry is projected to grow from USD 3.08 Billion in 2024 to USD 4.99 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.8% during the forecast period (2024 - 2032).
Scleritis is a medical condition that causes painful inflammation of sclera (white part of the eye). In some severe cases, the disease is reported to cause loss of vision, i.e., by affecting episclera and sclera. Thus, its timely diagnosis and treatment are necessary against scleritis. Focal redness or violaceous discoloration, scleral thickening, late scleral, and scleral necrosis are some of the prominent symptoms associated with the disease.
It is established that more than 50% of scleritis cases are associated with autoimmune disease, including rheumatoid arthritis. The prevalence of rheumatoid arthritis is increasing and, thus, the susceptible scleritis patient population. It is suggestive that the prevalence of rheumatoid arthritis was about 0.5–1.0% within regional boundaries of North America and Northern Europe. This scleritis market is indicating a positive market growth during the forecast period, 2022–2030.
Moreover, factors such as the growing aging population and increasing per capita healthcare expenditure boost the market growth. However, lack of awareness in the middle-income countries and the absence of targeted treatment is estimated to restraint the market growth during the forecast period.
Scleritis Market Segmentation
Scleritis market has been segmented into type, diagnostic test & treatment, end-user, and region.
The scleritis market, based on type, has been segmented into anterior scleritis and posterior scleritis. The anterior scleritis segment is further segmented into diffuse scleritis, nodular scleritis, and necrotizing scleritis.
The scleritis global market, by diagnostic test & treatment, has been divided into diagnostic tests and treatment. The diagnostic test market is further segmented into ultrasonography, complete blood count, biopsy, others.
The treatment segment is sub-divided into medication and surgery. The medication segment is further classified into corticosteroid, nonsteroidal anti-inflammatory drugs, and immunosuppressive drugs. The corticosteroid segment is sub-segmented into difluprednate, prednisolone, and others. The nonsteroidal anti-inflammatory drugs segment is further classified into aspirin, ibuprofen, and others. The immunosuppressive drugs segment is sub-segmented into methotrexate, mycophenolate, and others.
The end-user segment has been segmented into hospitals & clinics, diagnostic centers, and academic & research organizations.
Scleritis Market Key Players
- Amgen
- Amneal Pharmaceuticals LLC
- Baxter International Inc.
- Boehringer Ingelheim
- Fresenius Kabi USA, LLC
- Jubilant Cadista Pharmaceuticals Inc.
- Mylan Pharmaceuticals Inc.
- Novartis Pharmaceuticals
- Perrigo Company
- Roxane Laboratories, Inc.
- Sandoz Inc.
- Shanghai Henlius Biotech
- Teva Pharmaceuticals USA, Inc.
- West-Ward Pharmaceuticals
- Zydus Pharmaceuticals (USA) Inc.
Regional Market Summary
Geographically, the Americas is projected to lead the scleritis market. This can be attributed due to the presence of well-developed healthcare infrastructure and the increasing prevalence of scleritis within the Americas.
Europe is expected to hold the second-largest share of the scleritis market owing to government support and the presence of developed countries such as the UK, Germany, and France within the region.
The scleritis market in Asia-Pacific is segmented into China, Japan, India, Australia, South Korea, and the rest of the Asia-Pacific. The region is estimated to grow with the highest CAGR. High prevalence of scleritis, growing geriatric population, and increasing penetration of market players boost the regional market. In India, the mean age of scleritis patients is estimated to be about 55. This susceptible age group is expanding, which is growing the treatment-seeking patient pool.
The Middle East & Africa is anticipated to hold the least share of the market owing to the presence of poor economies, stringent government regulations, and low per capita income in Africa. Within the region, the Middle East is projected to lead the market owing to developed healthcare infrastructure and the presence of economies such as Saudi Arabia, Kuwait, and Dubai.
Scleritis Market, by Type
- Anterior Scleritis
- Diffuse Scleritis
- Nodular Scleritis
- Necrotizing Scleritis
- Posterior Scleritis
Scleritis Market, by Diagnostic Test & Treatment
- Diagnostic Test
- Ultrasonography
- Complete Blood Count
- Biopsy
- Others
- Treatment
- Medication
- Corticosteroid
- Difluprednate
- Prednisolone
- Others
- Nonsteroidal Anti-Inflammatory Drugs
- Aspirin
- Ibuprofen
- Others
- Immunosuppressive Drugs
- Methotrexate
- Mycophenolate
- Others
- Corticosteroid
- Surgery
- Medication
Scleritis Market, by End User
- Hospitals & Clinics
- Diagnostic Centers
- Academic & Research Organizations
Scleritis Market, by Region
- Americas
- North America
- US
- Canada
- South America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Intended Audience
- Pharmaceutical companies
- Medical devices companies
- Contract research organizations
- Contract manufacturing organizations
- Research and development organization
- Academics and research institutes
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
